Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16
Not intended for U.S. and UK Media – Aflibercept 8 mg late-breaking data at the 55th Annual Scientific Meeting 2022 of the Retina Society: Berlin, November 5, 2022 – Bayer AG today announced that detailed results from two pivotal clinical studies have demonstrated sustained visual acuity and anatomic improvements with aflibercept 8 mg with 12- …









